Loading
A phase 1/2 trial of Pembrolizumab, Carboplatin, Pemetrexed and Ifinatamab deruxtecan in non-small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) is a phase 1/2 interventional study registered as NCT04165070 by Merck Sharp & Dohme LLC, with 450 participants planned, started 2019-12-19 and due to reach its primary completion in 2032-02-13. Interventions recorded: Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed, Vibostolimab and Boserolimab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD), Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Merck & Co. (MSD), Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Merck & Co. (MSD), Carboplatin, Pembrolizumab and the tag pipeline.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.
Shares Pemetrexed, Carboplatin, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pemetrexed, Carboplatin, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/